Takeda Pharmaceutical Company Limited (NYSE:TAK - Get Free Report)'s share price reached a new 52-week high on Thursday . The stock traded as high as $15.37 and last traded at $15.19, with a volume of 2583891 shares changing hands. The stock had previously closed at $14.98.
Analyst Upgrades and Downgrades
Separately, Morgan Stanley raised Takeda Pharmaceutical from an "equal weight" rating to an "overweight" rating in a research report on Wednesday, April 2nd.
Check Out Our Latest Report on Takeda Pharmaceutical
Takeda Pharmaceutical Price Performance
The firm has a market cap of $44.69 billion, a PE ratio of 35.11, a price-to-earnings-growth ratio of 0.24 and a beta of 0.39. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.31 and a quick ratio of 0.72. The firm has a 50-day simple moving average of $14.40 and a 200 day simple moving average of $13.91.
Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last issued its quarterly earnings results on Thursday, January 30th. The company reported $0.42 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.34 by $0.08. Takeda Pharmaceutical had a net margin of 4.53% and a return on equity of 9.39%. As a group, equities analysts expect that Takeda Pharmaceutical Company Limited will post 1.64 EPS for the current year.
Institutional Trading of Takeda Pharmaceutical
Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Versant Capital Management Inc purchased a new position in Takeda Pharmaceutical during the fourth quarter valued at $26,000. Wilmington Savings Fund Society FSB purchased a new position in shares of Takeda Pharmaceutical in the 3rd quarter worth about $40,000. BNP Paribas Financial Markets boosted its stake in Takeda Pharmaceutical by 416.0% in the 3rd quarter. BNP Paribas Financial Markets now owns 3,220 shares of the company's stock worth $46,000 after purchasing an additional 2,596 shares in the last quarter. Farther Finance Advisors LLC grew its position in Takeda Pharmaceutical by 123.6% during the 4th quarter. Farther Finance Advisors LLC now owns 3,575 shares of the company's stock valued at $47,000 after purchasing an additional 1,976 shares during the last quarter. Finally, Crowley Wealth Management Inc. bought a new stake in Takeda Pharmaceutical during the 4th quarter valued at about $52,000. Hedge funds and other institutional investors own 9.17% of the company's stock.
About Takeda Pharmaceutical
(
Get Free Report)
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.
Featured Articles
Before you consider Takeda Pharmaceutical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Takeda Pharmaceutical wasn't on the list.
While Takeda Pharmaceutical currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
